메뉴 건너뛰기




Volumn 32, Issue 23, 2014, Pages 2703-2711

Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine

Author keywords

Conserved epitope; Cross protection; Gp96; Influenza vaccine; T cell response

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 96; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

EID: 84899932945     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.045     Document Type: Article
Times cited : (21)

References (52)
  • 1
    • 67650407532 scopus 로고    scopus 로고
    • Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans
    • Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
    • (2009) Science , vol.325 , pp. 197-201
    • Garten, R.J.1    Davis, C.T.2    Russell, C.A.3    Shu, B.4    Lindstrom, S.5    Balish, A.6
  • 2
    • 84872164097 scopus 로고    scopus 로고
    • The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus
    • Tan A.C., Deliyannis G., Bharadwaj M., Brown L.E., Zeng W., Jackson D.C. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2013, 91:96-104.
    • (2013) Immunol Cell Biol , vol.91 , pp. 96-104
    • Tan, A.C.1    Deliyannis, G.2    Bharadwaj, M.3    Brown, L.E.4    Zeng, W.5    Jackson, D.C.6
  • 3
    • 67349182104 scopus 로고    scopus 로고
    • Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes
    • Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87:300-308.
    • (2009) Immunol Cell Biol , vol.87 , pp. 300-308
    • Brown, L.E.1    Kelso, A.2
  • 4
    • 78649476854 scopus 로고    scopus 로고
    • Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development
    • Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010, 7:351.
    • (2010) Virol J , vol.7 , pp. 351
    • Stanekova, Z.1    Vareckova, E.2
  • 5
    • 84878284641 scopus 로고    scopus 로고
    • Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses
    • Liu D., Shi W., Shi Y., Wang D., Xiao H., Li W., et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013, 381:1926-1932.
    • (2013) Lancet , vol.381 , pp. 1926-1932
    • Liu, D.1    Shi, W.2    Shi, Y.3    Wang, D.4    Xiao, H.5    Li, W.6
  • 6
    • 47849097202 scopus 로고    scopus 로고
    • Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization
    • Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
    • (2008) Nat Immunol , vol.9 , pp. 847-856
    • Hornung, V.1    Bauernfeind, F.2    Halle, A.3    Samstad, E.O.4    Kono, H.5    Rock, K.L.6
  • 8
    • 34147181229 scopus 로고    scopus 로고
    • Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
    • Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25:3554-3560.
    • (2007) Vaccine , vol.25 , pp. 3554-3560
    • Ninomiya, A.1    Imai, M.2    Tashiro, M.3    Odagiri, T.4
  • 9
    • 84869086842 scopus 로고    scopus 로고
    • Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults
    • Nielsen A.B., Nielsen H.S., Nielsen L., Thybo S., Kronborg G. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine 2012, 30:7067-7071.
    • (2012) Vaccine , vol.30 , pp. 7067-7071
    • Nielsen, A.B.1    Nielsen, H.S.2    Nielsen, L.3    Thybo, S.4    Kronborg, G.5
  • 10
    • 84867899922 scopus 로고    scopus 로고
    • A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine
    • Langley J.M., Frenette L., Chu L., McNeil S., Halperin S., Li P., et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect Dis 2012, 12:279.
    • (2012) BMC Infect Dis , vol.12 , pp. 279
    • Langley, J.M.1    Frenette, L.2    Chu, L.3    McNeil, S.4    Halperin, S.5    Li, P.6
  • 11
    • 84861963478 scopus 로고    scopus 로고
    • The mechanism of action of MF59 - an innately attractive adjuvant formulation
    • O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
    • (2012) Vaccine , vol.30 , pp. 4341-4348
    • O'Hagan, D.T.1    Ott, G.S.2    De Gregorio, E.3    Seubert, A.4
  • 12
    • 84891473026 scopus 로고    scopus 로고
    • Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients
    • Son J., Lee S.B., Lee D.W., Kim I.Y., Lee S.J., Lee S.M., et al. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients. Clin Exp Nephrol 2013, 17:275-283.
    • (2013) Clin Exp Nephrol , vol.17 , pp. 275-283
    • Son, J.1    Lee, S.B.2    Lee, D.W.3    Kim, I.Y.4    Lee, S.J.5    Lee, S.M.6
  • 13
    • 77953125928 scopus 로고    scopus 로고
    • Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
    • Ansaldi F., Zancolli M., Durando P., Montomoli E., Sticchi L., Del Giudice G., et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010, 28:4123-4129.
    • (2010) Vaccine , vol.28 , pp. 4123-4129
    • Ansaldi, F.1    Zancolli, M.2    Durando, P.3    Montomoli, E.4    Sticchi, L.5    Del Giudice, G.6
  • 14
    • 79952411472 scopus 로고    scopus 로고
    • Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets
    • van den Brand J.M., Kreijtz J.H., Bodewes R., Stittelaar K.J., van Amerongen G., Kuiken T., et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 2011, 85:2851-2858.
    • (2011) J Virol , vol.85 , pp. 2851-2858
    • van den Brand, J.M.1    Kreijtz, J.H.2    Bodewes, R.3    Stittelaar, K.J.4    van Amerongen, G.5    Kuiken, T.6
  • 15
    • 77949657463 scopus 로고    scopus 로고
    • AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice
    • Caillet C., Piras F., Bernard M.C., de Montfort A., Boudet F., Vogel F.R., et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 28:3076-3079.
    • (2010) Vaccine , vol.28 , pp. 3076-3079
    • Caillet, C.1    Piras, F.2    Bernard, M.C.3    de Montfort, A.4    Boudet, F.5    Vogel, F.R.6
  • 16
    • 84857482098 scopus 로고    scopus 로고
    • The importance of adjuvant formulation in the development of a tuberculosis vaccine
    • Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 2012, 188:2189-2197.
    • (2012) J Immunol , vol.188 , pp. 2189-2197
    • Baldwin, S.L.1    Bertholet, S.2    Reese, V.A.3    Ching, L.K.4    Reed, S.G.5    Coler, R.N.6
  • 17
    • 77958498224 scopus 로고    scopus 로고
    • Vaccine adjuvants: putting innate immunity to work
    • Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
    • (2010) Immunity , vol.33 , pp. 492-503
    • Coffman, R.L.1    Sher, A.2    Seder, R.A.3
  • 18
    • 61549132283 scopus 로고    scopus 로고
    • A universal epitope-based influenza vaccine and its efficacy against H5N1
    • Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009, 27:2099-2107.
    • (2009) Vaccine , vol.27 , pp. 2099-2107
    • Adar, Y.1    Singer, Y.2    Levi, R.3    Tzehoval, E.4    Perk, S.5    Banet-Noach, C.6
  • 19
    • 84868283459 scopus 로고    scopus 로고
    • A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years
    • Antrobus R.D., Lillie P.J., Berthoud T.K., Spencer A.J., McLaren J.E., Ladell K., et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012, 7:e48322.
    • (2012) PLoS One , vol.7
    • Antrobus, R.D.1    Lillie, P.J.2    Berthoud, T.K.3    Spencer, A.J.4    McLaren, J.E.5    Ladell, K.6
  • 20
    • 84862219175 scopus 로고    scopus 로고
    • Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    • Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
    • (2012) Clin Infect Dis , vol.55 , pp. 19-25
    • Lillie, P.J.1    Berthoud, T.K.2    Powell, T.J.3    Lambe, T.4    Mullarkey, C.5    Spencer, A.J.6
  • 21
    • 79951645476 scopus 로고    scopus 로고
    • Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    • Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
    • (2011) Clin Infect Dis , vol.52 , pp. 1-7
    • Berthoud, T.K.1    Hamill, M.2    Lillie, P.J.3    Hwenda, L.4    Collins, K.A.5    Ewer, K.J.6
  • 22
    • 0035070198 scopus 로고    scopus 로고
    • CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
    • Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
    • (2001) Immunity , vol.14 , pp. 303-313
    • Basu, S.1    Binder, R.J.2    Ramalingam, T.3    Srivastava, P.K.4
  • 23
    • 0345305789 scopus 로고    scopus 로고
    • Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells
    • Berwin B., Hart J.P., Rice S., Gass C., Pizzo S.V., Post S.R., et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J 2003, 22:6127-6136.
    • (2003) EMBO J , vol.22 , pp. 6127-6136
    • Berwin, B.1    Hart, J.P.2    Rice, S.3    Gass, C.4    Pizzo, S.V.5    Post, S.R.6
  • 24
    • 1942501656 scopus 로고    scopus 로고
    • Essential role of CD91 in re-presentation of gp96-chaperoned peptides
    • Binder R.J., Srivastava P.K. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Nat Acad Sci USA 2004, 101:6128-6133.
    • (2004) Proc Nat Acad Sci USA , vol.101 , pp. 6128-6133
    • Binder, R.J.1    Srivastava, P.K.2
  • 25
    • 58749109185 scopus 로고    scopus 로고
    • Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses
    • De Filippo A., Binder R.J., Camisaschi C., Beretta V., Arienti F., Villa A., et al. Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol 2008, 181:6525-6535.
    • (2008) J Immunol , vol.181 , pp. 6525-6535
    • De Filippo, A.1    Binder, R.J.2    Camisaschi, C.3    Beretta, V.4    Arienti, F.5    Villa, A.6
  • 26
    • 77955669767 scopus 로고    scopus 로고
    • High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules
    • Matsutake T., Sawamura T., Srivastava P.K. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun 2010, 10:7.
    • (2010) Cancer Immun , vol.10 , pp. 7
    • Matsutake, T.1    Sawamura, T.2    Srivastava, P.K.3
  • 27
    • 49149084518 scopus 로고    scopus 로고
    • Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation
    • Robert J., Ramanayake T., Maniero G.D., Morales H., Chida A.S. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 2008, 180:3176-3182.
    • (2008) J Immunol , vol.180 , pp. 3176-3182
    • Robert, J.1    Ramanayake, T.2    Maniero, G.D.3    Morales, H.4    Chida, A.S.5
  • 28
    • 33747339222 scopus 로고    scopus 로고
    • Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses
    • Warger T., Hilf N., Rechtsteiner G., Haselmayer P., Carrick D.M., Jonuleit H., et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 2006, 281:22545-22553.
    • (2006) J Biol Chem , vol.281 , pp. 22545-22553
    • Warger, T.1    Hilf, N.2    Rechtsteiner, G.3    Haselmayer, P.4    Carrick, D.M.5    Jonuleit, H.6
  • 29
    • 84863115806 scopus 로고    scopus 로고
    • The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain
    • Wu S., Hong F., Gewirth D., Guo B., Liu B., Li Z. The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain. J Biol Chem 2012, 287:6735-6742.
    • (2012) J Biol Chem , vol.287 , pp. 6735-6742
    • Wu, S.1    Hong, F.2    Gewirth, D.3    Guo, B.4    Liu, B.5    Li, Z.6
  • 30
    • 33847260278 scopus 로고    scopus 로고
    • Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages
    • Yang Y., Liu B., Dai J., Srivastava P.K., Zammit D.J., Lefrancois L., et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 2007, 26:215-226.
    • (2007) Immunity , vol.26 , pp. 215-226
    • Yang, Y.1    Liu, B.2    Dai, J.3    Srivastava, P.K.4    Zammit, D.J.5    Lefrancois, L.6
  • 31
    • 84859101225 scopus 로고    scopus 로고
    • Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited
    • Randazzo M., Terness P., Opelz G., Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012, 130:2219-2231.
    • (2012) Int J Cancer , vol.130 , pp. 2219-2231
    • Randazzo, M.1    Terness, P.2    Opelz, G.3    Kleist, C.4
  • 32
    • 79951555513 scopus 로고    scopus 로고
    • Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant
    • Li Y., Song H., Li J., Wang Y., Yan X., Zhao B., et al. Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant. J Biotechnol 2011, 151:343-349.
    • (2011) J Biotechnol , vol.151 , pp. 343-349
    • Li, Y.1    Song, H.2    Li, J.3    Wang, Y.4    Yan, X.5    Zhao, B.6
  • 33
    • 34547837401 scopus 로고    scopus 로고
    • Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
    • Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
    • (2007) Lancet , vol.370 , pp. 580-589
    • Leroux-Roels, I.1    Borkowski, A.2    Vanwolleghem, T.3    Drame, M.4    Clement, F.5    Hons, E.6
  • 34
    • 47749108644 scopus 로고    scopus 로고
    • A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets
    • Joseph T., McAuliffe J., Lu B., Vogel L., Swayne D., Jin H., et al. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008, 378:123-132.
    • (2008) Virology , vol.378 , pp. 123-132
    • Joseph, T.1    McAuliffe, J.2    Lu, B.3    Vogel, L.4    Swayne, D.5    Jin, H.6
  • 35
    • 79952076763 scopus 로고    scopus 로고
    • Heat shock protein 70 inhibits the activity of influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo
    • Li G., Zhang J., Tong X., Liu W., Ye X. Heat shock protein 70 inhibits the activity of influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo. PLoS One 2011, 6:e16546.
    • (2011) PLoS One , vol.6
    • Li, G.1    Zhang, J.2    Tong, X.3    Liu, W.4    Ye, X.5
  • 36
    • 80051569840 scopus 로고    scopus 로고
    • Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
    • Wang S.F., Qiu L.P., Liu G.Z., Li Y., Zhang X.J., Jin W.S., et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine 2011, 29:6342-6351.
    • (2011) Vaccine , vol.29 , pp. 6342-6351
    • Wang, S.F.1    Qiu, L.P.2    Liu, G.Z.3    Li, Y.4    Zhang, X.J.5    Jin, W.S.6
  • 37
    • 84871645347 scopus 로고    scopus 로고
    • TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses
    • Zhao B., Wang Y., Zhang Y., Li Y., Zhang X., Xu Y., et al. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses. Vaccine 2013, 31:545-552.
    • (2013) Vaccine , vol.31 , pp. 545-552
    • Zhao, B.1    Wang, Y.2    Zhang, Y.3    Li, Y.4    Zhang, X.5    Xu, Y.6
  • 38
    • 70449334144 scopus 로고    scopus 로고
    • Treg suppress CTL responses upon immunization with HSP gp96
    • Liu Z., Li X., Qiu L., Zhang X., Chen L., Cao S., et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009, 39:3110-3120.
    • (2009) Eur J Immunol , vol.39 , pp. 3110-3120
    • Liu, Z.1    Li, X.2    Qiu, L.3    Zhang, X.4    Chen, L.5    Cao, S.6
  • 39
    • 78649395770 scopus 로고    scopus 로고
    • Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity
    • Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 2010, 84:12691-12702.
    • (2010) J Virol , vol.84 , pp. 12691-12702
    • Hong, D.K.1    Chang, S.2    Botham, C.M.3    Giffon, T.D.4    Fairman, J.5    Lewis, D.B.6
  • 40
    • 77949603728 scopus 로고    scopus 로고
    • A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models
    • Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
    • (2010) PLoS One , vol.5
    • Kistner, O.1    Crowe, B.A.2    Wodal, W.3    Kerschbaum, A.4    Savidis-Dacho, H.5    Sabarth, N.6
  • 41
    • 79953230918 scopus 로고    scopus 로고
    • Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development
    • Liu J., Zhang S., Tan S., Zheng B., Gao G.F. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Exp Biol Med (Maywood) 2011, 236:253-267.
    • (2011) Exp Biol Med (Maywood) , vol.236 , pp. 253-267
    • Liu, J.1    Zhang, S.2    Tan, S.3    Zheng, B.4    Gao, G.F.5
  • 43
    • 84871574987 scopus 로고    scopus 로고
    • Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice
    • Huang B., Wang W., Li R., Wang X., Jiang T., Qi X., et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J 2012, 9:322.
    • (2012) Virol J , vol.9 , pp. 322
    • Huang, B.1    Wang, W.2    Li, R.3    Wang, X.4    Jiang, T.5    Qi, X.6
  • 44
    • 84873349582 scopus 로고    scopus 로고
    • Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus
    • Kim M.C., Song J.M., Eunju O., Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492.
    • (2013) Mol Ther , vol.21 , pp. 485-492
    • Kim, M.C.1    Song, J.M.2    Eunju, O.3    Kwon, Y.M.4    Lee, Y.J.5    Compans, R.W.6
  • 45
    • 77954409486 scopus 로고    scopus 로고
    • An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
    • Zhao G., Sun S., Du L., Xiao W., Ru Z., Kou Z., et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010, 7:151.
    • (2010) Virol J , vol.7 , pp. 151
    • Zhao, G.1    Sun, S.2    Du, L.3    Xiao, W.4    Ru, Z.5    Kou, Z.6
  • 46
    • 84870696513 scopus 로고    scopus 로고
    • Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals
    • Liu J., Zhang S., Tan S., Yi Y., Wu B., Cao B., et al. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol 2012, 86:13281-13294.
    • (2012) J Virol , vol.86 , pp. 13281-13294
    • Liu, J.1    Zhang, S.2    Tan, S.3    Yi, Y.4    Wu, B.5    Cao, B.6
  • 47
    • 70349972479 scopus 로고    scopus 로고
    • PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants
    • Ichinohe T., Ainai A., Tashiro M., Sata T., Hasegawa H. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009, 27:6276-6279.
    • (2009) Vaccine , vol.27 , pp. 6276-6279
    • Ichinohe, T.1    Ainai, A.2    Tashiro, M.3    Sata, T.4    Hasegawa, H.5
  • 48
    • 84864492941 scopus 로고    scopus 로고
    • Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge
    • Wang X., Zhang W., Liu F., Zheng M., Zheng D., Zhang T., et al. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch Virol 2012, 157:1451-1461.
    • (2012) Arch Virol , vol.157 , pp. 1451-1461
    • Wang, X.1    Zhang, W.2    Liu, F.3    Zheng, M.4    Zheng, D.5    Zhang, T.6
  • 50
    • 77957906849 scopus 로고    scopus 로고
    • Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice
    • Huang M.H., Lin S.C., Hsiao C.H., Chao H.J., Yang H.R., Liao C.C., et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 2010, 5:e12279.
    • (2010) PLoS One , vol.5
    • Huang, M.H.1    Lin, S.C.2    Hsiao, C.H.3    Chao, H.J.4    Yang, H.R.5    Liao, C.C.6
  • 51
    • 84899965895 scopus 로고    scopus 로고
    • Placenta-derived gp96 as a multivalent prophylactic cancer vaccine
    • Zhao B., Wang Y., Wu B., Liu S., Wu E., Fan H., et al. Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Sci Rep 2013, 3:1947.
    • (2013) Sci Rep , vol.3 , pp. 1947
    • Zhao, B.1    Wang, Y.2    Wu, B.3    Liu, S.4    Wu, E.5    Fan, H.6
  • 52
    • 70449719118 scopus 로고    scopus 로고
    • Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
    • Qian J., Hong S., Wang S., Zhang L., Sun L., Wang M., et al. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 2009, 114:3880-3889.
    • (2009) Blood , vol.114 , pp. 3880-3889
    • Qian, J.1    Hong, S.2    Wang, S.3    Zhang, L.4    Sun, L.5    Wang, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.